DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriersSequence changes in predicted promoter elements of STK11/LKB1 are unlikely to contribute to Peutz-Jeghers syndromeThe rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urineGenetic testing and common disorders in a public health framework: how to assess relevance and possibilities. Background Document to the ESHG recommendations on genetic testing and common disordersUBE2QL1 is disrupted by a constitutional translocation associated with renal tumor predisposition and is a novel candidate renal tumor suppressor geneMechanisms of inherited cancer susceptibilityGenome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer riskGermline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.Diagnosis and Management of Hereditary Thyroid CancerCandidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer riskGenome-wide association study identifies a common variant associated with risk of endometrial cancer.Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation CarriersPeutz-Jeghers disease: most, but not all, families are compatible with linkage to 19p13.3.Ethical, social and economic issues in familial breast cancer: a compilation of views from the E.C. Biomed II Demonstration ProjectGuidelines for follow-up of women at high risk for inherited breast cancer: consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer.Exploring the link between MORF4L1 and risk of breast cancer.Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT studyWhole-gene APC deletions cause classical familial adenomatous polyposis, but not attenuated polyposis or "multiple" colorectal adenomas.Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.Lymphocyte telomere length is long in BRCA1 and BRCA2 mutation carriers regardless of cancer-affected status.Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk.Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriersAssociations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriersBreast cancer susceptibility polymorphisms and endometrial cancer risk: a Collaborative Endometrial Cancer Study.An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriersMutation cluster region, association between germline and somatic mutations and genotype-phenotype correlation in upper gastrointestinal familial adenomatous polyposis.Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.Genome-wide association study identifies a possible susceptibility locus for endometrial cancerComprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancerFine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation CarriersMeta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1.Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers.CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancerIdentification of a C/G polymorphism in the promoter region of the BRCA1 gene and its use as a marker for rapid detection of promoter deletions.Five endometrial cancer risk loci identified through genome-wide association analysis.No evidence that GATA3 rs570613 SNP modifies breast cancer risk.
P50
Q21144874-5D092A3B-EA4D-4ECA-8188-E2B43F59D345Q21266604-744B9DB2-0FA5-4880-A22E-9311FE9DA463Q21562160-2499AC41-1F9E-418C-8DA1-9181B7609B98Q22330767-F123D0D5-25E3-4C04-8743-AFDE5354A45CQ24321830-12ABEB9B-2059-4C66-94AF-FE0D0BDF88C8Q24679752-4671C4B9-9D1E-43E6-978F-873D2CBE2FA9Q27008356-5359FA63-0192-43E3-8469-F793ECF92E37Q27852185-C8C2C944-3C4D-49F4-B0EA-0DDD39932577Q28274820-CB872C0B-2BA8-484E-A402-2DB67F9E4547Q28385765-6CFD338F-4D78-4F02-9A7C-6208C8097FF7Q29417135-2FB3DBA3-1593-4D79-A1B8-77AEB16C0455Q30252854-1135B185-6B97-45FC-863F-40D94CB842E1Q33614244-0740278C-B2F4-4B77-B8E2-F247D89C7E25Q33680045-77C91FCA-55AC-4928-AC9E-BD5A280F5FCEQ33792801-D66466CB-6D5D-4888-AD78-A286574858F2Q33792814-37BEFFFB-A8BD-4230-9E3C-DD1DABC7D6AEQ33863235-E5F2CDD2-59E4-44FA-A774-31EE43FBCECBQ33927384-C21E21AC-09B5-48B0-A4D2-451C77ACE06FQ34015467-735706F4-0F27-4680-A760-F1B39E0D392DQ34327945-A817575D-2A16-4FCF-B7A1-D3E182008E78Q34394665-F1F15F60-0020-4CA8-B524-6405D06B4213Q34700093-E24AFBB2-CF32-4991-94A4-C99CE576B91EQ35022825-8E11E658-410A-4262-B5B5-46C9529FB372Q35063160-05ECFBDD-6C60-48BB-B46D-2793F173E6E0Q35382206-473D2F57-4432-4BB1-86DB-0B6B1E7351ABQ35523236-7658149F-DBA5-4ADA-9840-42A968A3F8D6Q35562912-0DC084F8-A7CD-4B15-99C7-F6A33DCDB55CQ35618307-C88ABDB6-98CD-46CD-AB40-EF031E493A00Q35747921-BB25A9A7-88AB-472B-9CCF-00AF8CEBB286Q35957703-1841FFF8-B76B-406F-92BF-2D760F2BA34CQ36024614-B3429765-CEBC-4133-B0F4-2EA921B58F1BQ36026731-8E61F198-6966-4ADA-A83B-0C1391DB4D21Q36087170-50267017-FA41-483A-89AC-2861BB7CA0E9Q36333368-72F9807A-835A-4E7D-9C42-22502E1A4722Q36356727-F0FDFAEF-0F2B-48EB-8295-FD240CAB23EFQ36393232-289E9322-EC14-4E73-94C4-B7EF3F32E82FQ36419325-7BB0E4A7-F259-47B2-8968-60A458E2626BQ36618927-ACBD0F93-9764-42EB-BCE5-C65908720478Q37002930-540378FD-1784-4647-A3BF-4D59E85C0110Q37308596-4CAD6CBC-BF30-4CBA-9A7A-8E6E25C67B0B
P50
description
British geneticist
@en
British geneticist
@en-ca
British geneticist
@en-gb
britische Genetikerin
@de
geneticista británica
@pt
geneticus
@nl
genetista britainiarra
@eu
genetista britannica
@it
genetista britànica
@ca
genetista británica
@es
name
Shirley Hodgson
@af
Shirley Hodgson
@an
Shirley Hodgson
@ast
Shirley Hodgson
@bar
Shirley Hodgson
@br
Shirley Hodgson
@ca
Shirley Hodgson
@co
Shirley Hodgson
@cs
Shirley Hodgson
@cy
Shirley Hodgson
@da
type
label
Shirley Hodgson
@af
Shirley Hodgson
@an
Shirley Hodgson
@ast
Shirley Hodgson
@bar
Shirley Hodgson
@br
Shirley Hodgson
@ca
Shirley Hodgson
@co
Shirley Hodgson
@cs
Shirley Hodgson
@cy
Shirley Hodgson
@da
altLabel
Shirley Penrose
@en
Shirley Victoria Hodgson
@en
Shirley Victoria Penrose
@en
prefLabel
Shirley Hodgson
@af
Shirley Hodgson
@an
Shirley Hodgson
@ast
Shirley Hodgson
@bar
Shirley Hodgson
@br
Shirley Hodgson
@ca
Shirley Hodgson
@co
Shirley Hodgson
@cs
Shirley Hodgson
@cy
Shirley Hodgson
@da
P3373
P1006
P1015
P214
P244
P268
P269
P5587
P906
P1006
P1015
P106
P1477
Shirley Victoria Penrose
@en-gb
P21
P213
0000 0000 8079 0540